Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas

被引:59
作者
Drumm, Michael R. [1 ]
Dixit, Karan S. [2 ]
Grimm, Sean [2 ]
Kumthekar, Priya [2 ]
Lukas, Rimas V. [2 ]
Raizer, Jeffrey J. [2 ]
Stupp, Roger [2 ]
Chheda, Milan G. [3 ]
Kam, Kwok-Ling [4 ]
McCord, Matthew [4 ]
Sachdev, Sean [5 ]
Kruser, Timothy [5 ]
Steffens, Alicia [1 ]
Javier, Rodrigo [1 ]
McCortney, Kathleen [1 ]
Horbinski, Craig [1 ,4 ]
机构
[1] Northwestern Univ, Dept Neurol Surg, Chicago, IL 60611 USA
[2] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA
[3] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[4] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA
[5] Northwestern Univ, Dept Radiat Oncol, Chicago, IL 60611 USA
关键词
glioblastoma; midbrain; pons; medulla; brainstem; postmortem; autopsy; SUPRATENTORIAL GLIOBLASTOMA; TEMOZOLOMIDE; BEVACIZUMAB; DISSEMINATION; POSTMORTEM; MULTIFORME; INVASION; PHASE; TRIAL;
D O I
10.1093/neuonc/noz216
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Progress in extending the survival of glioblastoma (GBM) patients has been slow. A better understanding of why patient survival remains poor is critical to developing new strategies. Postmortem studies on GBM can shed light on why patients are dying. Methods. The brains of 33 GBM patients were autopsied and examined for gross and microscopic abnormalities. Clinical-pathologic correlations were accomplished through detailed chart reviews. Data were compared with older published autopsy GBM studies that predated newer treatment strategies, such as more extensive surgical resection and adjuvant temozolomide. Results. In older GBM autopsy series, mass effect was observed in 72% of brains, with herniation in 50% of all cases. Infiltration of tumor into the brainstem was noted in only 21% of those older cases. In the current series, only 10 of 33 (30%) GBMs showed mass effect (P = 0.0003), and only 1 (3%) showed herniation (P < 0.0001). However, extensive GBM infiltration of the brainstem was present in 22 cases (67%, P < 0.0001), with accompanying destruction of the pons and white matter tracts. There was a direct correlation between longer median patient survival and the presence of brainstem infiltration (16.1 mo in brainstem-invaded cases vs 9.0 mo in cases lacking extensive brainstem involvement; P = 0.0003). Conclusions. With improving care, severe mass effect appears to be less common in GBM patients today, whereas dissemination, including life-threatening brainstem invasion, is now more pronounced. This has major implications regarding preclinical GBM models, as well as the design of clinical trials aimed at further improving patient survival.
引用
收藏
页码:470 / 479
页数:10
相关论文
共 32 条
  • [21] CEREBRAL GLIOBLASTOMA WITH CEREBROSPINAL-FLUID DISSEMINATION - A CLINICOPATHOLOGICAL STUDY OF 14 CASES EXAMINED BY COMPLETE AUTOPSY
    ONDA, K
    TANAKA, R
    TAKAHASHI, H
    TAKEDA, N
    IKUTA, F
    [J]. NEUROSURGERY, 1989, 25 (04) : 533 - 540
  • [22] THE CAUSE OF DEATH IN PATIENTS WITH GLIOBLASTOMA IS MULTIFACTORIAL - CLINICAL FACTORS AND AUTOPSY FINDINGS IN 117 CASES OF SUPRATENTORIAL GLIOBLASTOMA IN ADULTS
    SILBERGELD, DL
    ROSTOMILY, RC
    ALVORD, EC
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1991, 10 (02) : 179 - 185
  • [23] Symptoms and problems in the end-of-life phase of high-grade glioma patients
    Sizoo, Eefje M.
    Braam, Lies
    Postma, Tjeerd J.
    Pasman, H. Roeline W.
    Heimans, Jan J.
    Klein, Martin
    Reijneveld, Jaap C.
    Taphoorn, Martin J. B.
    [J]. NEURO-ONCOLOGY, 2010, 12 (11) : 1162 - 1166
  • [24] Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Stupp, R
    Mason, WP
    van den Bent, MJ
    Weller, M
    Fisher, B
    Taphoorn, MJB
    Belanger, K
    Brandes, AA
    Marosi, C
    Bogdahn, U
    Curschmann, J
    Janzer, RC
    Ludwin, SK
    Gorlia, T
    Allgeier, A
    Lacombe, D
    Cairncross, JG
    Eisenhauer, E
    Mirimanoff, RO
    Van Den Weyngaert, D
    Kaendler, S
    Krauseneck, P
    Vinolas, N
    Villa, S
    Wurm, RE
    Maillot, MHB
    Spagnolli, F
    Kantor, G
    Malhaire, JP
    Renard, L
    De Witte, O
    Scandolaro, L
    Vecht, CJ
    Maingon, P
    Lutterbach, J
    Kobierska, A
    Bolla, M
    Souchon, R
    Mitine, C
    Tzuk-Shina, T
    Kuten, A
    Haferkamp, G
    de Greve, J
    Priou, F
    Menten, J
    Rutten, I
    Clavere, P
    Malmstrom, A
    Jancar, B
    Newlands, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) : 987 - 996
  • [25] Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
    Stupp, Roger
    Taillibert, Sophie
    Kanner, Andrew
    Read, William
    Steinberg, David M.
    Lhermitte, Benoit
    Toms, Steven
    Idbaih, Ahmed
    Ahluwalia, Manmeet S.
    Fink, Karen
    Di Meco, Francesco
    Lieberman, Frank
    Zhu, Jay-Jiguang
    Stragliotto, Giuseppe
    Tran, David D.
    Brem, Steven
    Hottinger, Andreas F.
    Kirson, Eilon D.
    Lavy-Shahaf, Gitit
    Weinberg, Uri
    Kim, Chae-Yong
    Paek, Sun-Ha
    Nicholas, Garth
    Burna, Jordi
    Hirte, Hal
    Weller, Michael
    Palti, Yoram
    Hegi, Monika
    Ram, Zvi
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (23): : 2306 - 2316
  • [26] NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
    Stupp, Roger
    Wong, Eric T.
    Kanner, Andrew A.
    Steinberg, David
    Engelhard, Herbert
    Heidecke, Volkmar
    Kirson, Eilon D.
    Taillibert, Sophie
    Liebermann, Frank
    Dbaly, Vladimir
    Ram, Zvi
    Villano, J. Lee
    Rainov, Nikolai
    Weinberg, Uri
    Schiff, David
    Kunschner, Lara
    Raizer, Jeffrey
    Honnorat, Jerome
    Sloan, Andrew
    Malkin, Mark
    Landolfi, Joseph C.
    Payer, Franz
    Mehdorn, Maximilian
    Weil, Robert J.
    Pannullo, Susan C.
    Westphal, Manfred
    Smrcka, Martin
    Chin, Lawrence
    Kostron, Herwig
    Hofer, Silvia
    Bruce, Jeffrey
    Cosgrove, Rees
    Paleologous, Nina
    Palti, Yoram
    Gutin, Philip H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (14) : 2192 - 2202
  • [27] Factors associated with a higher rate of distant failure after primary treatment for glioblastoma
    Tejada, Sonia
    Diez-Valle, Ricardo
    Aldave, Guillermo
    Marigil, Miguel
    de Gallego, Jaime
    Daniel Dominguez, Pablo
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2014, 116 (01) : 169 - 175
  • [28] Mutant IDH1 and thrombosis in gliomas
    Unruh, Dusten
    Schwarze, Steven R.
    Khoury, Laith
    Thomas, Cheddhi
    Wu, Meijing
    Chen, Li
    Chen, Rui
    Liu, Yinxing
    Schwartz, Margaret A.
    Amidei, Christina
    Kumthekar, Priya
    Benjamin, Carolina G.
    Song, Kristine
    Dawson, Caleb
    Rispoli, Joanne M.
    Fatterpekar, Girish
    Golfinos, John G.
    Kondziolka, Douglas
    Karajannis, Matthias
    Pacione, Donato
    Zagzag, David
    McIntyre, Thomas
    Snuderl, Matija
    Horbinski, Craig
    [J]. ACTA NEUROPATHOLOGICA, 2016, 132 (06) : 917 - 930
  • [29] BRAIN-STEM AND SPINAL METASTASES OF SUPRATENTORIAL GLIOBLASTOMA-MULTIFORME - A CLINICAL-SERIES
    VERTOSICK, FT
    SELKER, RG
    [J]. NEUROSURGERY, 1990, 27 (04) : 516 - 522
  • [30] Lomustine and Bevacizumab in Progressive Glioblastoma
    Wick, Wolfgang
    Gorlia, Thierry
    Bendszus, Martin
    Taphoorn, Martin
    Sahm, Felix
    Harting, Inga
    Brandes, Alba A.
    Taal, Walter
    Domont, Julien
    Idbaih, Ahmed
    Campone, Mario
    Clement, Paul M.
    Stupp, Roger
    Fabbro, Michel
    Le Rhun, Emilie
    Dubois, Francois
    Weller, Michael
    von Deimling, Andreas
    Golfinopoulos, Vassilis
    Bromberg, Jacoline C.
    Platten, Michael
    Klein, Martin
    van den Bent, Martin J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1954 - 1963